Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 18, 2018--The “Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Peripheral Arterial Disease Peripheral Vascular Disease - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD) and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 3, 1, 11, 9, 1, 9 and 3 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics CoveredIntroduction Overview Therapeutics Development Therapeutics Assessment Companies Involved in Therapeutics Development Drug Profiles Dormant Projects Discontinued Products Product Development Milestones Companies FeaturedAlfaSigma SpAAnGes IncARCA biopharma IncAthera Biotechnologies ABAthersys IncBayer AGBetagenon ABBiogenCell LtdCardioVascular BioTherapeutics IncCelularity IncDiffusion Pharmaceuticals IncHemostemix IncHuman Stem Cells InstituteID Pharma Co LtdJuventas Therapeutics IncLipimetiX Development IncNovartis AGProteon Therapeutics IncRecardio GmbHResverlogix CorpReven Pharmaceuticals IncStemedica Cell Technologies IncSymic Biomedical IncVESSL Therapeutics LtdViroMed Co LtdYuyu Pharma Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/lrsd5b/peripheral?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180918005551/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Cardiovascular Drugs
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CARDIOLOGY CLINICAL TRIALS PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/18/2018 08:15 AM/DISC: 09/18/2018 08:15 AM